Product Program year 2019 Source: CMS Open Payments

Vyvanse

Drug Central Nervous System (CNS)

NDC 59417-116-01

Open in the dashboard

General payments

$386,191

14,460 payments

Research payments

$0

0 payments

Through program year 2019, $386,191 in general payments and $0 in research payments were reported against Vyvanse (Central Nervous System (CNS)).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2019 General $386,191 14,460

Breakdown

Who paid General payments · program year 2019
  1. Takeda Pharmaceuticals U.S.A., Inc. $386,191 14,460 payments
Top recipients General payments · program year 2019
  1. Rakesh Jain Psychiatry · Lake Jackson, TX $7,191 2% · 10 payments
  2. Gregory Mattingley Psychiatry · Saint Charles, MO $7,138 2% · 9 payments
  3. Andrew Cutler Psychiatry · Lakewood Ranch, FL $6,861 2% · 11 payments
  4. Richard Weisler Psychiatry · Raleigh, NC $6,580 2% · 9 payments
  5. Louis Kuritzky Family Medicine · Gainesville, FL $6,391 2% · 11 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Psychiatry Psychiatry & Neurology $177,781 46% · 640 practitioners
  2. Family Medicine $59,819 16% · 2,449 practitioners
  3. Pediatrics $46,007 12% · 2,014 practitioners
  4. Child & Adolescent Psychiatry Psychiatry & Neurology $35,770 9% · 91 practitioners
  5. Internal Medicine $28,906 8% · 963 practitioners

The top 5 of 77 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Texas $37,126 10% · 553 recipients
  2. Florida $33,227 9% · 391 recipients
  3. Tennessee $29,187 8% · 333 recipients
  4. New York $27,028 7% · 462 recipients
  5. Georgia $21,918 6% · 276 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

111,664

Prescriptions dispensed, refills included

Drug cost

$45,630,501

Paid at the pharmacy, in all

Prescribers

5,823

With 11 or more claims of it

Medicare Part D drugs matched to Vyvanse, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Vyvanse Lisdexamfetamine Dimesylate Same name 5,823 111,664 $45,630,501

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Christopher Laganke Neurology AL 467 $177,362 None on record
Glenda McConnell Nurse Practitioner WI 179 $91,729 None on record
John Strunk Psychiatry AL 177 $68,313 None on record
Rogelio Silva Psychiatry KY 147 $56,595 None on record
Edward Sathoff Psychiatry MN 141 $60,007 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
14,460 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record